Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival

Author(s): ShuangYi Lei*, ShanShan Tian, SongMei Lu, Zhou Qing, JianLin Long, LuChun Li and Dan Yang*

Volume 24, Issue 12, 2024

Published on: 15 April, 2024

Page: [954 - 960] Pages: 7

DOI: 10.2174/0118715206294031240404071838

Price: $65

Abstract

Background: Primary Pulmonary Lymphoepithelioma-like Carcinoma (PPLELC) is a rare form of cancer for which no standard treatment has been established to date. Patients with advanced-stage PPLELC generally have a poor prognosis with overall survival of 22.7 months.

Case Presentation: Here, we report a case of advanced primary pulmonary lymphoepithelioma-like carcinoma. Initially, the patient underwent a first-line (GP) and a second-line (DP) of chemotherapy, which provided temporary relief but resulted in varying degrees of myelosuppression. When the disease progressed again, we administered a third-line treatment consisting of camrelizumab combined with anlotinib.

Result: This resulted in a progression-free survival of over 26 months without significant toxic side effects.

Conclusion: Our findings suggest that combining camrelizumab and anlotinib could lead to a long progressionfree survival in patients with advanced PPLELC.

« Previous
Graphical Abstract

[1]
Bégin, L.R.; Eskandari, J.; Joncas, J.; Panasci, L. Epstein‐barr virus related lymphoepithelioma‐like carcinoma of lung. J. Surg. Oncol., 1987, 36(4), 280-283.
[http://dx.doi.org/10.1002/jso.2930360413] [PMID: 2826922]
[2]
Han, A.; Xiong, M.; Zong, Y. Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China. Am. J. Clin. Pathol., 2000, 114(2), 220-226.
[http://dx.doi.org/10.1309/148K-ND54-6NJX-NA61] [PMID: 10941337]
[3]
Chang, Y.L.; Wu, C.T.; Shih, J.Y.; Lee, Y.C. New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am. J. Surg. Pathol., 2002, 26(6), 715-723.
[http://dx.doi.org/10.1097/00000478-200206000-00004] [PMID: 12023575]
[4]
Castro, C.Y.; Ostrowski, M.L.; Barrios, R.; Green, L.K.; Popper, H.H.; Powell, S.; Cagle, P.T.; Ro, J.Y. Relationship between epstein-barr virus and lymphoepithelioma-like carcinoma of the lung: A clinicopathologic study of 6 cases and review of the literature. Hum. Pathol., 2001, 32(8), 863-872.
[http://dx.doi.org/10.1053/hupa.2001.26457] [PMID: 11521232]
[5]
Zhou, Y. Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease. Lung Cancer, 2019, 138, 116-123.
[6]
Archwamety, A.; Ruangchira-urai, R.; Akewanlop, C.; Korphaisarn, K. Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review. Thorac. Cancer, 2022, 13(17), 2539-2541.
[http://dx.doi.org/10.1111/1759-7714.14580] [PMID: 35830974]
[7]
Fang, W.; Hong, S.; Chen, N.; He, X.; Zhan, J.; Qin, T.; Zhou, T.; Hu, Z.; Ma, Y.; Zhao, Y.; Tian, Y.; Yang, Y.; Xue, C.; Tang, Y.; Huang, Y.; Zhao, H.; Zhang, L. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget, 2015, 6(32), 33019-33032.
[http://dx.doi.org/10.18632/oncotarget.5028] [PMID: 26361045]
[8]
Yi, M.; Jiao, D.; Qin, S. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer, 2019, 18(1), 60.
[http://dx.doi.org/10.1186/s12943-019-0974-6]
[9]
Chang, Y.L.; Wu, C.T.; Shih, J.Y.; Lee, Y.C. Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma‐like carcinomas. Cancer Sci., 2011, 102(1), 282-287.
[http://dx.doi.org/10.1111/j.1349-7006.2010.01768.x] [PMID: 21070477]
[10]
Curcio, L.D.; Cohen, J.S.; Paz, I.B.; Grannis, F.W., Jr; Chilcote, R.; Weiss, L.M. Primary lymphoepithelioma-like carcinoma of the lung in a child. Report of an Epstein-Barr virus-related neoplasm. Chest, 1997, 111(1), 250-251.
[http://dx.doi.org/10.1378/chest.111.1.250] [PMID: 8996028]
[11]
Hoxworth, J.M.; Hanks, D.K.; Araoz, P.A.; Elicker, B.M.; Reddy, G.P.; Webb, W.R.; Leung, J.W.T.; Gotway, M.B. Lymphoepithelioma-like carcinoma of the lung: Radiologic features of an uncommon primary pulmonary neoplasm. AJR Am. J. Roentgenol., 2006, 186(5), 1294-1299.
[http://dx.doi.org/10.2214/AJR.05.0244] [PMID: 16632721]
[12]
Chan, J.K.C.; Hui, P.K.; Tsang, W.Y.W.; Law, C.K.; Ma, C.C.; Yip, T.T.C.; Poon, Y.F. Primary lymphoepithelioma-like carcinoma of the lung. A clinicopathologic study of 11 cases. Cancer, 1995, 76(3), 413-422.
[http://dx.doi.org/10.1002/1097-0142(19950801)76:3<413:AID-CNCR2820760311>3.0.CO;2-X] [PMID: 8625122]
[13]
Yoshino, N.; Kubokura, H.; Yamauchi, S.; Ohaki, Y.; Koizumi, K.; Shimizu, K. Lymphoepithelioma-like carcinoma of the lung. Jpn. J. Thorac. Cardiovasc. Surg., 2005, 53(12), 653-656.
[http://dx.doi.org/10.1007/BF02665079] [PMID: 16408473]
[14]
Xie, M.; Wu, X.; Wang, F. Clinical significance of plasma epstein-barr virus DNA in pulmonary Lymphoepithelioma-like Carcinoma (LELC). Patients. J. Thorac. Oncol., 2018, 13(2), 218-227.
[http://dx.doi.org/10.1016/j.jtho.2017.10.031]
[15]
Han, A.; Xiong, M.; Gu, Y.; Lin, S.; Xiong, M. Lymphoepithelioma-like carcinoma of the lung with a better prognosis. A clinicopathologic study of 32 cases. Am. J. Clin. Pathol., 2001, 115(6), 841-850.
[http://dx.doi.org/10.1309/BUAN-BGFW-69U9-C3H8] [PMID: 11392880]
[16]
Xie, Z.; Liu, L.; Lin, X. A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. Modern Pathol., 2020, 33, 626-638.
[http://dx.doi.org/10.1038/s41379-019-0391-9]
[17]
Kim, C.; Rajan, A.; Debrito, P.A.; Giaccone, G. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: A case report and focused review of literature. Transl. Lung Cancer Res., 2016, 5(6), 720-726.
[http://dx.doi.org/10.21037/tlcr.2016.11.06] [PMID: 28149767]
[18]
Narayanan, A.; Knollmann, F.D.; Walby, J. EBV positive primary pulmonary Lymphoepithelioma-Like Carcinoma (LELC) Response to PD-L1 Blockade. Clin. Lung Cancer, 2018, 20, 20.
[PMID: 30679078]
[19]
Qiu, Z.X.; Zhou, P.; Wang, K. Primary pulmonary lymphoepithelioma-like carcinoma response favorably to nivolumab: A case report. OncoTargets Ther., 2019, 12, 8595-8600.
[http://dx.doi.org/10.2147/OTT.S219512] [PMID: 31802895]
[20]
Xiao, Y.; He, J.; Luo, S. Comparison of immunotherapy, chemotherapy, and chemoimmunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma: A retrospective study. Front. Oncol., 2022, 12, 820302.
[http://dx.doi.org/10.3389/fonc.2022.820302]
[21]
Tang, Z.; Fang, R.; Tong, G. Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature. Lung Cancer, 2020, 146, 335-340.
[http://dx.doi.org/10.1016/j.lungcan.2020.06.027]
[22]
Dolesche, D. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J. Exp. Clin. Cancer Res., 2021, 40, 288.
[23]
Manegold, C. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J. Thorac. Oncol., 2017, 12, 194-207.
[24]
Han, B.; Li, K.; Wang, Q.; Zhang, L.; Shi, J.; Wang, Z.; Cheng, Y.; He, J.; Shi, Y.; Zhao, Y.; Yu, H.; Zhao, Y.; Chen, W.; Luo, Y.; Wu, L.; Wang, X.; Pirker, R.; Nan, K.; Jin, F.; Dong, J.; Li, B.; Sun, Y. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer. JAMA Oncol., 2018, 4(11), 1569-1575.
[http://dx.doi.org/10.1001/jamaoncol.2018.3039] [PMID: 30098152]
[25]
Chu, T.; Zhong, R. Zhong, H Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J. Thorac. Oncol., 2021, 16(4), 643-652.
[http://dx.doi.org/10.1016/j.jtho.2020.11.026]
[26]
Wang, P.; Fang, X.; Yin, T. Efficacy and safety of Anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study. Front. Oncol., 2021, 11, 628124.
[http://dx.doi.org/10.3389/fonc.2021.628124]
[27]
Liu, S.; Qin, T.; Liu, Z. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis., 2020, 11(5), 309.
[http://dx.doi.org/10.1038/s41419-020-2511-3]
[28]
Liu, Y.; Long, L.; Liu, J. Case report: Anlotinib reverses nivolumab resistance in advanced primary pulmonary lymphoepithelioma-like carcinoma with FGFR3 gene amplification. Front. Oncol., 2021, 11, 749682.
[http://dx.doi.org/10.3389/fonc.2021.749682]
[29]
Ramjiawan, R.R.; Griffioen, A.W.; Duda, D.G. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis, 2017, 20(2), 185-204.
[http://dx.doi.org/10.1007/s10456-017-9552-y]
[30]
Lee, W.S.; Yang, H.; Chon, H.J. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med., 2020, 52(9), 1475-1485.
[http://dx.doi.org/10.1038/s12276-020-00500-y]
[31]
Ren, S.; He, J.; Fang, Y. Camrelizumab plus Apatinib in treatment-naive patients with advanced nonsquamous NSCLC: A multicenter, open-label, single-arm, phase 2 trial. JTO Clin. Res. Rep., 2022, 3(5), 100312.
[http://dx.doi.org/10.1016/j.jtocrr.2022.100312]
[32]
Kudo, M.; Finn, R.S.; Cheng, A.L. Albumin-Bilirubin grade analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc analysis of the Phase III IMbrave150 study. Liver Cancer, 2023, 12(5), 479-493.
[http://dx.doi.org/10.1159/000529996]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy